Repression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages

scientific article published in December 2017

Repression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.INTIMP.2017.11.032
P698PubMed publication ID29202299

P2093author name stringOlivier Fardel
Valérie Lecureur
Abdullah Mayati
Marie Febvre-James
Yu Augagneur
P2860cites workInfection of a human hepatoma cell line by hepatitis B virusQ34388628
P921main subjectruxolitinibQ7383611
P304page(s)354-365
P577publication date2017-12-01
P1433published inInternational ImmunopharmacologyQ15751306
P1476titleRepression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages
P478volume54

Reverse relations

cites work (P2860)
Q96618090COVID-19: review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking
Q63246372Characterization and Transcript Expression Analyses of Atlantic Cod
Q91587430Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib
Q92954842Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis
Q95276341SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc
Q107547771SARS-CoV-2 disrupts proximal elements in the JAK-STAT pathway
Q97416174The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19

Search more.